skip to content


GSK shingles vaccine recommended by advisory committee

26 October 2017 08:30

The US Centres for Disease Control and Prevention's advisory committee on immunisation practices has voted in favour of three recommendations for the use of GlaxoSmithKline's Shingrix for the prevention of shingles.

GSK said the new recommendations meant up to 62 million more adults in the US should be immunised, approximately 42 million aged 50-59 years old and 20 million who had previously been vaccinated against shingles.

GSK senior vice-president and chief medical officer of GSK Vaccines, Dr. Thomas Breuer, said: 'After the age of 50, a person's risk for shingles increases.

'As our immune system ages, all of us become more vulnerable to shingles.

'GSK developed Shingrix specifically to overcome the age-related decline in immunity.'

He said the vote was an important step forward for the prevention of shingles, as the expanded recommendation would bring access to a vaccine with efficacy of greater than 90%, which would help protect more American adults from a painful and serious condition.

Shingrix was approved by the US Food and Drug Administration on 20 Oct for use in adults aged 50 years and older.

At 8:30am: (LON:GSK) GlaxoSmithKline PLC share price was -15.75p at 1413.25p

Story provided by

Related Company: GSK

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Aberdeen Ediston

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.